A study presented at a medical conference in Barcelona showed that using AstraZeneca’s immunotherapy drug, Imfinzi, both before and after surgery improved survival rates in patients with bladder cancer. This treatment reduced the risk of death by 25% compared to chemotherapy alone and lowered the risk of disease recurrence by about a third. The results were described as “transformative” by AstraZeneca’s head of oncology R&D, Susan Galbraith. The Phase 3 NIAGARA trial results were presented at the conference and published in the New England Journal of Medicine, potentially changing how muscle-invasive bladder tumors are treated.
Source link
AstraZeneca’s Imfinzi increases survival rates in bladder cancer
